CA2270118A1 - Composes nitroses et nitrosyles inhibiteurs de la phosphodiesterase, compositions comprenant ces composes et utilisations correspondantes - Google Patents

Composes nitroses et nitrosyles inhibiteurs de la phosphodiesterase, compositions comprenant ces composes et utilisations correspondantes Download PDF

Info

Publication number
CA2270118A1
CA2270118A1 CA002270118A CA2270118A CA2270118A1 CA 2270118 A1 CA2270118 A1 CA 2270118A1 CA 002270118 A CA002270118 A CA 002270118A CA 2270118 A CA2270118 A CA 2270118A CA 2270118 A1 CA2270118 A1 CA 2270118A1
Authority
CA
Canada
Prior art keywords
compound
formula
defined above
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002270118A
Other languages
English (en)
Inventor
David S. Garvey
Inigo Saenz De Tejada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitromed Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/740,764 external-priority patent/US5874437A/en
Application filed by Individual filed Critical Individual
Publication of CA2270118A1 publication Critical patent/CA2270118A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paper (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des inhibiteurs nitrosés et/ou nitrosylés de la phosphodiestérase, l'inhibiteur étant représenté par la formule NO¿n?-PDE dans laquelle "n" vaut 1 ou 2. Un tel inhibiteur de la phosphodiestérase peut être nitrosé ou nitrosylé par des sites tels que l'oxygène (condensation hydroxyl), le soufre (condensation sulfhydryl), le carbone et de l'azote. L'invention concerne également des compositions comprenant de tels composés associés à un excipient pharmaceutiquement admis. L'invention concerne par ailleurs une composition comprenant une quantité thérapeutiquement active d'un inhibiteur de la phosphodiestérase (inhibiteur PDE) qui peut être éventuellement substitué par un ou plusieurs groupes fonctionnels NO ou NO¿2? et un excédant molaire de un à dix fois d'un composé qui donne, transfère ou libère du monoxyde d'azote sous forme d'espèce chargée, en l'occurrence de nitrosinium (NO?+¿) ou de nitroxyl (NO?-¿), ou sous forme d'espèce neutre, en l'occurrence l'oxyde nitrique (NO?.¿), qui stimule la production endogène d'EDRF. L'invention concerne en outre des compositions intégrant de tels composés dans un excipient pharmaceutiquement admis. L'invention concerne enfin un traitement dirigé contre l'impuissance masculine et consistant à administrer ces composés et des compositions à base de tels composés.
CA002270118A 1996-11-01 1997-10-31 Composes nitroses et nitrosyles inhibiteurs de la phosphodiesterase, compositions comprenant ces composes et utilisations correspondantes Abandoned CA2270118A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/740,764 1996-11-01
US08/740,764 US5874437A (en) 1996-11-01 1996-11-01 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
PCT/US1997/019870 WO1998019672A1 (fr) 1996-11-01 1997-10-31 Composes nitroses et nitrosyles inhibiteurs de la phosphodiesterase, compositions comprenant ces composes et utilisations correspondantes

Publications (1)

Publication Number Publication Date
CA2270118A1 true CA2270118A1 (fr) 1998-05-14

Family

ID=26792881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002270118A Abandoned CA2270118A1 (fr) 1996-11-01 1997-10-31 Composes nitroses et nitrosyles inhibiteurs de la phosphodiesterase, compositions comprenant ces composes et utilisations correspondantes

Country Status (5)

Country Link
EP (1) EP0941086A4 (fr)
JP (1) JP2001504457A (fr)
AU (1) AU722480B2 (fr)
CA (1) CA2270118A1 (fr)
WO (1) WO1998019672A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
EP1535611A3 (fr) * 1997-06-23 2009-09-16 Strakan International Limited Thérapie de conditions vasculaires par des microdoses de doneurs de NO
EP1027054A4 (fr) * 1997-10-28 2002-11-04 Vivus Inc Apport local d'inhibiteurs de phosphodiesterases, dans le traitement du dysfonctionnement erectile
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US6627632B2 (en) 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
CN1526448A (zh) * 1998-12-14 2004-09-08 ���ռ�ҩ��ɷ����޹�˾ 用于治疗***直肠病的药物和方法
US6476037B1 (en) 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
WO2002022127A1 (fr) * 2000-09-13 2002-03-21 Isis Innovation Limited Utilisation d"inhibiteurs de phosphodiesterase pour le traitement de trouble ano-rectal
AU2002338528B2 (en) 2001-05-02 2008-01-24 Nicox S.A. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
KR20040010713A (ko) * 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
WO2003030823A2 (fr) 2001-10-05 2003-04-17 Combinatorx, Incorporated Combinaisons permettant le traitement des troubles inflammatoires
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7875268B2 (en) 2004-04-06 2011-01-25 L'oreal S.A. Dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
EP1786814B1 (fr) 2004-08-25 2010-03-31 Actelion Pharmaceuticals Ltd. Dérivés du bicyclononène employés en tant qu'inhibiteurs de la rénine
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
MX2007014722A (es) 2005-05-27 2008-02-15 Actelion Pharmaceuticals Ltd Nuevos derivados de amida de acido piperidin carboxilico.
WO2007016677A2 (fr) 2005-08-02 2007-02-08 Nitromed, Inc. Composes antimicrobiens promoteurs d'oxyde nitrique, compositions et procedes d'utilisation
CN101379033A (zh) 2006-02-02 2009-03-04 埃科特莱茵药品有限公司 新颖二级胺
EP2007705A4 (fr) 2006-03-29 2011-09-07 Nicox Sa Prostaglandines amplificatrices d'oxyde nitrique, compositions et méthodes d'utilisation
WO2009135299A1 (fr) 2008-05-05 2009-11-12 Merck Frosst Canada Ltd. Dérivés de pipéridine substitués en 3,4 utilisés en tant qu'inhibiteurs de la rénine
NZ597022A (en) 2009-06-09 2014-05-30 Prolong Pharmaceuticals Llc Hemoglobin compositions
EP3630769A1 (fr) * 2017-05-22 2020-04-08 Topadur Pharma AG Nouveaux activateurs de la guanylate cyclase solubles à double mode d'action, inhibiteurs de phosphodiestérase et leurs utilisations
WO2022022669A1 (fr) * 2020-07-30 2022-02-03 Biofront Therapeutics (Beijing) Co., Ltd. Composés à double fonction et leurs procédés d'utilisation
CA3187693A1 (fr) * 2020-07-30 2022-02-03 Zheng Huang Conjugues de medicament comprenant de l'apremilast et un groupe oxyde nitrique, et utilisations connexes
WO2023005180A1 (fr) * 2021-07-30 2023-02-02 Biofront Therapeutics (Beijing) Co., Ltd. Composés à double fonction et leurs procédés d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU179019B (en) * 1978-11-01 1982-08-28 Gyogyszekutato Intezet Process for preparing 4-//3,4-dialkoxy-phenyl/-alkyl/- 2imidazolidinone derivatives
US5459145A (en) * 1988-01-19 1995-10-17 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
US4714705A (en) * 1986-07-07 1987-12-22 Ortho Pharmaceutical Corporation 4-nitrogen substituted isoquinolinol compounds having cardiotonic, phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8928346D0 (en) * 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
GB8929208D0 (en) * 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
IE73235B1 (en) * 1991-03-25 1997-05-21 Akzo Nv 4-aryl-thiazole or imidazole derivatives
US5380758A (en) * 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
WO1993012068A1 (fr) * 1991-12-11 1993-06-24 Brigham And Women's Hospital S-nitrosothiols utilises comme decontracturants des muscles lisses et leurs utilisations therapeutiques
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
ES2176252T3 (es) * 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
CA2143143A1 (fr) * 1994-03-08 1995-09-09 Toshihiko Tanaka Derives de la 3-phenylpyrrolidine
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
GB9608408D0 (en) * 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction

Also Published As

Publication number Publication date
AU5196298A (en) 1998-05-29
AU722480B2 (en) 2000-08-03
EP0941086A4 (fr) 2000-07-12
WO1998019672A1 (fr) 1998-05-14
JP2001504457A (ja) 2001-04-03
EP0941086A1 (fr) 1999-09-15

Similar Documents

Publication Publication Date Title
US5874437A (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU722480B2 (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5958926A (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1998019672A9 (fr) Composes nitroses et nitrosyles inhibiteurs de la phosphodiesterase, compositions comprenant ces composes et utilisations correspondantes
US6514934B1 (en) Imidazoline α-adrenergic receptor antagonist compounds in combination with nitric oxide donors, compositions and methods of use
EP1018879B1 (fr) Composes d'antagonistes nitroses ou nitrosyles du recepteur alpha-adrenergique, leurs compositions et utilisations
US6331543B1 (en) Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
EP1852422A2 (fr) Composés antagonistes des récepteurs alpha-andrénergiques nitrosés et nitrosylés, compositions et leurs utilisations
USRE37234E1 (en) Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6472425B1 (en) Methods for treating female sexual dysfunctions
US20020061879A1 (en) Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US20050065161A1 (en) Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US20030158184A1 (en) Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US20060063774A1 (en) Phosphodiesterase inhibitor compounds and nitric oxide donors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead